HALB (Halberd) Research & Development : $ Mil (TTM As of Jul. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Halberd Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Halberd's Research & Development for the six months ended in Jul. 2023 was $0.30 Mil. Halberd does not have enough years/quarters to calculate the Research & Development for the trailing twelve months (TTM) ended in Jul. 2023.

Halberd Research & Development Historical Data

The historical data trend for Halberd's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd Research & Development Chart

Halberd Annual Data

Trend

Jul08

Jul22

Jul23

Research & Development

0.91

0.30

Halberd Semi-Annual Data
	Jul08	Jul22	Jul23
Research & Development	-	0.91	0.30

Halberd Research & Development Calculation

This is the expense the company spent on research and development.

Halberd (OTCPK:HALB) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Halberd Research & Development Related Terms

Thank you for viewing the detailed overview of Halberd's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Halberd Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 25, Jackson Center, PA, USA, 16133

Website

https://www.halberdcorporation.com

Halberd Corp is a holding company and acquisition vehicle for established businesses. It is also developing a patented process for disease eradication by removing the pathophysiologic basis of the disease. The company is focused on developing treatments for neurodegenerative diseases, such as PTSD and CTE (Post Traumatic Stress Disorder and Chronic Traumatic Encephalopathy), Alzheimer's Disease, Parkinson's Disease, etc.

Executives

John Christopher Maddox	director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO	10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist	director, 10 percent owner, officer: CEO, Secretary and Director	24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr.	director	50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas	director	280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236